On March 25, 2019, the Board of Directors of Xeris Pharmaceuticals, Inc. accepted the resignation of Jonathan Rigby, a class I director, effective as of the expiration of his current term at the Company’s 2019 annual meeting of stockholders. Mr. Rigby has been a member of the Board since 2016. He serves on the Board’s audit committee and is the Chairman of the Board’s nominating and corporate governance committee. In connection with Mr. Rigby’s resignation, the Board approved the following appointments to the committees of the Board, to be effective immediately following the Company’s 2019 annual meeting of stockholders, as: John Schmid as Chair of Audit Committee, BJ Bormann and Marla Persky as members of Audit Committee. BJ Bormann as Chair of Compensation Committee, Dawn Halkuff, John Schmid and Jeffrey Sherman as members of Compensation Committee, Marla Persky as Chair of Nominating and Corporate Governance Committee, Dawn Halkuff and Jeffrey Sherman as members of Nominating and Corporate Governance Committee.